CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I clinical trial of its proprietary first-in-class …
Follow this link:
Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014